Rethinking phase 2 trials in amyotrophic lateral sclerosis

Overview of attention for article published in Brain, December 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet
twitter: 12 X users

bluesky: 13 Bluesky users

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 14 X posts from 12 X users, with an upper bound of 51,569 followers.

Rethinking phase 2 trials in amyotrophic lateral sclerosis https://t.co/vJy1xDCPa9 Well-thought out discussion - basically if you want to run 6-month Phase 2 trials - use biomarkers for your go/no-go decision. If you want to use ALSFRS-R - you need a l…

Rethinking phase 2 trials in amyotrophic lateral sclerosis: https://t.co/KBV0hDqrZ5

#ALS #MND https://t.co/I9Dvwuoj7s

RT @MND_RIA: Very thoughtful and topical discussion paper; Rethinking phase 2 trials in amyotrophic lateral sclerosis https://t.co/vJy1xDC…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.